BioCardia (BCDA) vs Dyadic International (DYAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCardia (BCDA) has outperformed Dyadic International (DYAI) over the past year, losing 25.4% versus a loss of 60.7%. Over five years, DYAI leads with a -90.8% price change compared with -97.6% for BCDA. Dyadic International is the larger company by market cap ($17.8 million vs $16.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCDA | DYAI |
|---|---|---|
| Share price | $1.06 | $0.4444 |
| Market cap | $16.05M | $17.80M |
| 1-day change | -2.75% | -2.65% |
| YTD return | -15.20% | -52.72% |
| 1-year return | -25.35% | -60.67% |
| 5-year return | -97.59% | -90.84% |
| EPS (TTM) | $-0.64 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.80 | $1.60 |
| 52-week low | $0.75 | $0.34 |
| Distance from 52-week high | -41.11% | -72.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +1362.26% | +1137.62% |
| Average volume | 282.05K | 201.91K |
| Shares outstanding | 15.14M | 40.06M |
| Employees | 17 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed DYAI by 35.3 percentage points over the past year.
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Healthcare · Biotechnology · 5 employees
BCDA vs DYAI FAQ
Which is bigger, BioCardia or Dyadic International?
Dyadic International (DYAI) is larger, with a market capitalization of $17.80M compared with $16.05M for BioCardia (BCDA).
Which stock has performed better over the past year, BCDA or DYAI?
BCDA returned -25.35% over the past 12 months, compared with -60.67% for DYAI (price return, excluding dividends). Past performance does not predict future results.
Are BioCardia and Dyadic International in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.